Considering new treatment paradigms for neuropsychiatric symptoms of Alzheimer's disease.
Hurvitz Brain Sciences Program, Sunnybrook Research Institute, University of Toronto, Canada; Departments of Psychiatry and Pharmacology, University of Toronto, Canada.
Krista L
KL
Lanctôt
Department of Neurology, Harvard Medical School, Cambridge, MA, USA; Center for Brain/Mind Medicine, Brigham and Women's Hospital, Boston, MA, USA; Voyager Therapeutics, Cambridge, MA, USA.
Brendon P
BP
Boot
Independent Science Writer, Elverson, PA, USA.
Lisa J
LJ
Bain
Division of Medical & Scientific Relations, Alzheimer's Association, Chicago, IL, USA. Electronic address: jhendrix@alz.org.
James A
JA
Hendrix
Division of Medical & Scientific Relations, Alzheimer's Association, Chicago, IL, USA.
Maria C
MC
Carrillo
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology*; D006801:Humans; D011619:Psychotropic Drugs / Q000627:therapeutic use
D011619:Psychotropic Drugs